| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

4 April 2024

ORYZON receives the INNOVATIVE SME seal from the Spanish Ministry of Science and Innovation

26 February 2024

ORYZON reports financial results and corporate update for quarter ended December 31, 2023

18-20 March 2024

BIO-Europe Spring 2024

CCIB

Barcelona

Spain

28-29 February 2024

17th Annual European Life Sciences CEO Forum

Hilton Zurich Airport Hotel

Zurich

Switzerland

14-15 February 2024

Bio-Neuroscience

Rosarium

Amsterdam

Netherlands

4-7 February 2024

Keystone Symposia Epigenetic Mechanisms and Cancer Treatment

Eldorado Hotel & Spa, Santa Fe

NM

United States

5 February 2024

ORYZON to provide corporate progress updates at several events in February-March

25 January 2024

Oryzon Virtual KOL Event to Discuss Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder

19 January 2024

ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024

7 January 2024

Webcast/Conference call hold by Oryzon to Discuss Topline Results from Phase IIb PORTICO Study of vafidemstat in Borderline Personality Disorder

Pagination

First page «
Previous page ‹
Page 1
Page 2
Page 3
Page 4
Current page 5
Page 6
Page 7
Page 8
Page 9
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel